Daré Bioscience Income Statement Analysis
Values in millions USD
| Breakdown | TTM | FY 2025 | FY 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Sep 2026 | Dec 2025 | Mar 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Mar 2019 | Dec 2017 |
| Revenue & Gross Profit | ||||||||||||
| Revenue | 1.41 | 1.03 | 0.01 | 0.01 | 2.81 | 10.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.84 | 0.30 | 14.31 | 14.31 | 21.64 | 30.14 | 0.10 | 0.10 | 0.08 | 0.01 | 0.63 | 0.00 |
| Gross Profit | -0.42 | 0.73 | -14.30 | 0.01 | -18.83 | -20.14 | -0.10 | -0.10 | -0.08 | -0.01 | 0.00 | 0.00 |
| Operating Expenses | ||||||||||||
| Research & Development | 1.34 | 5.52 | 14.21 | 14.31 | 21.54 | 30.04 | 30.62 | 30.62 | 20.77 | 8.55 | 6.41 | 0.98 |
| Selling, General & Administrative | 9.06 | 8.76 | 9.16 | 9.16 | 11.91 | 11.24 | 8.35 | 8.35 | 6.55 | 5.79 | 5.28 | 2.71 |
| Operating Expenses | 10.11 | 14.29 | 9.16 | 23.46 | 11.91 | 41.39 | 38.97 | 38.97 | 27.32 | 14.33 | 11.70 | 3.69 |
| Operating Income | -10.53 | -13.55 | -23.45 | -23.45 | -30.74 | -31.39 | -39.07 | -39.07 | -27.40 | -14.34 | -16.88 | -11.18 |
| Other Income/Expense | ||||||||||||
| Interest Income | - | 0.68 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | - | 0.82 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.32 |
| Other Income/Expense | -0.05 | 0.15 | 19.40 | 19.40 | 0.78 | 0.44 | 0.37 | 0.37 | 0.00 | 0.08 | 143.50 | -0.32 |
| Income | ||||||||||||
| Income Before Tax | -10.58 | -13.40 | -4.05 | -4.05 | -30.16 | -30.95 | -38.70 | -38.70 | -27.40 | -14.26 | -16.74 | -11.50 |
| Income Tax Expense | - | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 10.23 | 0.00 |
| Net Income | -10.58 | -13.40 | -4.05 | -4.05 | -30.16 | -30.95 | -38.70 | -38.70 | -27.40 | -14.26 | -16.74 | -11.50 |
| Net Income - Continuous Operations | -10.58 | -13.40 | -4.05 | -4.05 | -30.16 | -30.95 | -38.70 | -38.70 | -27.40 | -14.26 | -16.74 | -11.50 |
| Net Income - Discontinued Operations | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -8.16 | -11.92 | -4.01 | -23.41 | -30.70 | -31.36 | -38.67 | -39.04 | -27.36 | -14.25 | -11.69 | -11.18 |
| EBIT | -10.53 | -13.55 | - | -23.45 | -30.74 | -31.39 | - | -39.07 | -27.40 | - | - | - |
| Depreciation & Amortization | 2.17 | 1.63 | 0.04 | 0.04 | 0.04 | 0.02 | 0.03 | 0.03 | 0.04 | 0.01 | 0.00 | 2.73 |
| Earnings Per Share | ||||||||||||
| Basic EPS | -0.38 | -1.20 | - | -0.48 | -4.15 | -4.44 | -8.00 | -7.59 | -11.00 | -11.00 | -30.00 | -4.00 |
| Diluted EPS | -0.38 | -1.20 | - | -0.48 | -4.15 | -4.44 | -8.00 | -7.59 | -11.00 | -11.00 | -30.00 | -4.00 |
| Basic Shares Outstanding | 15.33 | 11.18 | 8.50 | 8.50 | 7.28 | 7.05 | 5.10 | 5.10 | 2.51 | 1.30 | 0.89 | 0.27 |
| Diluted Shares Outstanding | 15.33 | 11.18 | 8.50 | 8.50 | 7.28 | 7.05 | 5.10 | 5.10 | 2.51 | 1.30 | 0.89 | 0.27 |
Source: Company financial statements from annual and quarterly filings. Data as of Sep 30, 2026. Data sources and methodology
